New Mexico Educational Retirement Board Purchases Shares of 38,600 Hims & Hers Health, Inc. (NYSE:HIMS)

New Mexico Educational Retirement Board acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 38,600 shares of the company's stock, valued at approximately $1,141,000.

A number of other institutional investors have also made changes to their positions in HIMS. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after acquiring an additional 933 shares during the last quarter. Tsfg LLC bought a new position in shares of Hims & Hers Health during the 1st quarter valued at about $46,000. Fifth Third Bancorp raised its holdings in shares of Hims & Hers Health by 165.4% during the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after acquiring an additional 961 shares during the period. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health in the 4th quarter valued at about $38,000. 63.52% of the stock is owned by institutional investors.

Insider Activity

In related news, COO Melissa Baird sold 33,333 shares of Hims & Hers Health stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the sale, the chief operating officer owned 805,083 shares in the company, valued at approximately $20,755,039.74. This trade represents a 3.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $56.76, for a total transaction of $7,272,488.52. Following the sale, the chief executive officer owned 160,215 shares in the company, valued at approximately $9,093,803.40. This trade represents a 44.44% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 667,014 shares of company stock valued at $34,394,653. 17.71% of the stock is owned by insiders.

Hims & Hers Health Stock Up 6.6%

Shares of Hims & Hers Health stock traded up $3.17 during trading hours on Monday, reaching $51.06. 22,954,217 shares of the company's stock were exchanged, compared to its average volume of 23,898,599. The business has a fifty day moving average of $53.68 and a two-hundred day moving average of $41.14. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The company has a market capitalization of $11.43 billion, a P/E ratio of 74.09, a price-to-earnings-growth ratio of 1.76 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm's quarterly revenue was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.05 earnings per share. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Piper Sandler restated a "neutral" rating and set a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their price objective for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $39.58.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.